Showing 5081-5090 of 9575 results for "".
- DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its Melanoma Testhttps://practicaldermatology.com/news/dermtech-adds-approximately-7-million-covered-lives-for-the-foundational-assay-of-its-melanoma-test/2461861/DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced a favorable coverage policy from Highmark Inc. (Highmark). Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, We
- GlobalSkin’s GRIDD Study to Measure True Impact of Skin Diseases Across the Globehttps://practicaldermatology.com/news/globalskins-gridd-study-to-measure-true-impact-of-skin-diseases-across-the-globe/2461856/The International Alliance of Dermatology Patient Organizations (GlobalSkin), in partnership with Cardiff University (UK), and University Medical Centre Hamburg-Eppendorf (Germany), launched the Global Research on the
- NY Dermatologist Louise Kaufmann, MD, Wins an International Award for Social Responsibility in Dermatology from L’Oréal and ILDShttps://practicaldermatology.com/news/dr-louise-kaufmann-wins-an-international-awards-for-social-responsibility-in-dermatology-from-loreal-and-ilds/2461842/Louise Kaufmann, MD, a general and cosmetic dermatologist in Great Neck, New York, took home an International Award for Social Responsibility in Dermatology for her efforts to provide access to dermatological care in rural and underserved areas of Jamaica. The awards, sp
- Merz Aesthetics to Distribute AccuVein’s Visualization Systemhttps://practicaldermatology.com/news/merz-aesthetics-to-distribute-accuveins-visualization-system/2461829/Merz Aesthetics is now the sole authorized distributor of AccuVein’s vein visualization system in the U.S. aesthetics market. A limited initial AccuVein field pilot yielded positive results and significant expansion of both new customers and Merz Aesthetics portfolio adoption. Bas
- Dermatology Around the Globe: First JAK for AD Approved in Indiahttps://practicaldermatology.com/news/dermatology-around-the-globe-first-jak-for-ad-approved-in-india/2461828/Intas Pharmaceuticals Ltd launched TOFATAS –a Drugs Controller General of India (DCGI) -approved, Tofacitinib Ointment 2% w/w for the treatment of mild to moderate Atopic Dermatitis (AD) in patients 18 years and above experiencing flare-ups of the disease. "The
- New Microneedle Patch May Treat Acne Without Antibioticshttps://practicaldermatology.com/news/new-microneedle-patch-may-treat-infected-acne-without-antibiotics/2461826/Researchers out of the University of Hong Kong (HKUMed) have designed a new microneedle patch that offers a non-antibiotic approach for the treatment of infected acne. The design is engineered with ultrasound-responsive zinc-based metal-organic framework (MOF) antibacterial nanoparticle
- Scleroderma Research Update from Cedars-Sinai’s Kao Autoimmunity Institutehttps://practicaldermatology.com/news/scleroderma-research-update-from-cedars-sinais-kao-autoimmunity-institute/2461818/An estimated 100,000 people in the U.S. are living with scleroderma, an autoimmune disease characterized by thickening and scarring of the skin and vital organs, and the narrowing of the blood vessels which lead to poor circulation. Tthere are about 7,000 to 8,000 new cases every year.
- VisualDx, Vaseline Join Forces to Advance Education on Treating Skin of Colorhttps://practicaldermatology.com/news/visualdx-vaseline-join-forces-to-advance-education-on-treating-skin-of-color/2461817/VisualDx and
- In With the Old: Curettage and Cryosurgery Still Effective for BCChttps://practicaldermatology.com/news/in-with-the-old-curettage-and-cryosurgery-still-effective-for-bcc/2461815/The combination of curettage and cryosurgery is a safe and effective treatment method for basal cell carcinoma, and now, a new study presents the results from testing different variants of the method. The current study, which appears in the Journal of the American Academy of Dermat
- US FDA Nod for Pfizer's Alopecia Drughttps://practicaldermatology.com/news/us-fda-nod-for-pfizers-alopecia-drug/2461814/The US Food and Drug Administration (FDA) approved Litfulo (ritlecitinib, Pfizer Inc) for severe alopecia areata in individuals 12 years of age and older. A kinase inhibitor that targets Janus kinase 3 (JAK3) and the tyrosine kinase expressed in the hepatocellular carcinoma (TEC) f